A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell LungNeoplasm Metastasis
- Interventions
- Registration Number
- NCT06119581
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
- Detailed Description
Dose Optimization, Part A, and Part B are randomized. Safety Lead-In for Part B is single arm, non-randomized.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1016
-
Histologically or cytologically confirmed NSCLC with Stage IIIB-IIIC or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy.
-
Part B and Safety Lead-In Part B: the histology of the tumor must be predominantly non-squamous (in line with pemetrexed label).
-
Must have disease with evidence of KRAS G12C mutation.
-
Must have known programmed death-ligand 1 (PD-L1) expression
- Part A: Greater than or equal to (≥)50 percent (%).
- Part B: 0% to 100%.
-
Must have measurable disease per RECIST v1.1.
-
Must have an ECOG performance status of 0 or 1.
-
Estimated life expectancy ≥12 weeks.
-
Ability to swallow capsules.
-
Must have adequate laboratory parameters.
-
Contraceptive use should be consistent with local regulations for those participating in clinical studies.
-
Women of childbearing potential must
- Have a negative pregnancy test.
- Not be breastfeeding during treatment
-
Have a documented additional validated targetable oncogenic driver mutation or alteration in genes such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF (V600E), human epidermal growth factor receptor 2 (HER2), MET (exon 14), ROS1, rearranged during transfection (RET), or neurotrophic tyrosine receptor kinase (NTRK)1/2/3.
-
Have had any of the following prior to randomization:
-- Prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for advanced or metastatic NSCLC.
--- 1 cycle of standard-of-care treatment prior to study enrollment will be allowed for cases where immediate treatment is clinically indicated:
-
Have known active central nervous system metastases and/or carcinomatous meningitis.
Exclusion Criteria for Participants receiving Pemetrexed and Platinum (Part B and Safety Lead-In Part B)
- Have predominantly squamous cell histology for NSCLC
- Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)
- Is unable or unwilling to take folic acid or vitamin B12 supplementation.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Dose Optimization: LY3537982 Dose Level 1 plus Pembrolizumab LY3537982 LY3537982 Dose level 1 administered orally in combination with pembrolizumab administered intravenously (IV) in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Dose Optimization: LY3537982 Dose Level 1 plus Pembrolizumab Pembrolizumab LY3537982 Dose level 1 administered orally in combination with pembrolizumab administered intravenously (IV) in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Dose Optimization: LY3537982 Dose Level 2 plus Pembrolizumab LY3537982 LY3537982 Dose level 2 administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Dose Optimization: LY3537982 Dose Level 2 plus Pembrolizumab Pembrolizumab LY3537982 Dose level 2 administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Safety Lead In: LY3537982 plus Pembrolizumab, Pemetrexed and Platinum LY3537982 LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Safety Lead In: LY3537982 plus Pembrolizumab, Pemetrexed and Platinum Pembrolizumab LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Safety Lead In: LY3537982 plus Pembrolizumab, Pemetrexed and Platinum Cisplatin LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Safety Lead In: LY3537982 plus Pembrolizumab, Pemetrexed and Platinum Carboplatin LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Safety Lead In: LY3537982 plus Pembrolizumab, Pemetrexed and Platinum Pemetrexed LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part A: LY3537982 plus Pembrolizumab LY3537982 LY3537982 administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part A: LY3537982 plus Pembrolizumab Pembrolizumab LY3537982 administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part A: Placebo plus Pembrolizumab Pembrolizumab Placebo administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part A: Placebo plus Pembrolizumab Placebo Placebo administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: LY3537982 plus Pembrolizumab, Pemetrexed, and Platinum LY3537982 LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: LY3537982 plus Pembrolizumab, Pemetrexed, and Platinum Pembrolizumab LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: LY3537982 plus Pembrolizumab, Pemetrexed, and Platinum Cisplatin LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: LY3537982 plus Pembrolizumab, Pemetrexed, and Platinum Carboplatin LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: LY3537982 plus Pembrolizumab, Pemetrexed, and Platinum Pemetrexed LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: Placebo plus Pembrolizumab, Pemetrexed, and Platinum Pembrolizumab Placebo administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: Placebo plus Pembrolizumab, Pemetrexed, and Platinum Placebo Placebo administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: Placebo plus Pembrolizumab, Pemetrexed, and Platinum Cisplatin Placebo administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: Placebo plus Pembrolizumab, Pemetrexed, and Platinum Carboplatin Placebo administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: Placebo plus Pembrolizumab, Pemetrexed, and Platinum Pemetrexed Placebo administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
- Primary Outcome Measures
Name Time Method Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE) Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year) Dose Optimization and Safety Lead-In Part B: Number of Participants with a TEAE
Part A and Part B: Progression-Free Survival (PFS) Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year) PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent central review (BICR)
- Secondary Outcome Measures
Name Time Method Part A and Part B: Overall Survival (OS) Randomization to date of death from any cause. (Estimated as up to 3 years) Part A and Part B: OS
Part A and Part B: Overall Response Rate (ORR): Percentage of Participants who Achieve a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) Randomization to disease progression or death. (Estimated as approximately 1 year) ORR per RECIST v1.1 by BICR
Part A and Part B: Duration of Response (DOR) Date of first evidence of CR or PR to date of disease progression or death from any cause. (Estimated as approximately 1 year) DOR per RECIST v1.1 by BICR
Part A and Part B: Disease Control Rate (DCR): Percentage of Participants who Achieve a BOR of CR, PR, or Stable Disease (SD) Randomization to disease progression or death from any cause. (Estimated as approximately 1 year) DCR per RECIST v1.1 by BICR
Part A and Part B: Time to Response (TTR) Time from randomization until the date that measurement criteria for CR or PR (whichever is first recorded) are first met (Estimated as approximately 1 year) TTR per RECIST v1.1 by BICR
Part A and Part B: Intracranial Overall Response Rate (ORR) Randomization to intracranial disease progression or death. (Estimated as approximately 1 year) Intracranial ORR per RECIST v1.1 by BICR
Part A and Part B: Intracranial Duration of Response (DoR) Date of first evidence of CR or PR to date of intracranial disease progression or death from any cause. (Estimated as approximately 1 year) Intracranial DoR per RECIST v1.1 by BICR
Part A and Part B: PFS2 Randomization to disease progression on next line of treatment or death from any cause (Estimated as approximately 1 year Part A and Part B: PFS2 by Investigator
Part A and Part B: Changes in NSCLC-related symptoms as measured by NSCLC-SAQ Randomization through end of treatment (Estimated as approximately 1 year)] NSCLC-related symptoms are assessed by the NSCLC-SAQ total score, which is computed as the sum of the 5 domains (7 questions) and ranges from 0 to 20. The total score will be calculated if all 7 questions are completed. Higher scores indicate more severe symptomatology.
Part A and Part B: Time to Worsening of NSCLC-related Symptoms as Measured by NSCLC Symptom Assessment Questionnaire (NSCLC-SAQ) Randomization through end of treatment (Estimated as approximately 1 year) NSCLC symptoms will be assessed using the 7-item NSCLC-SAQ. The NSCLC-SAQ measures overall symptom severity of NSCLC, including cough, pain, dyspnea, fatigue, and poor appetite. Response options range from 0) "Not at all" to 4) "Always" or from 0) "Never" to 4) "Always." The total score ranges from 0-20. Higher scores represent worse symptoms.
Part A and Part B: Changes in physical function, as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (EORTC QLQ-C30) Physical Functioning subscale and IL19 Randomization through end of treatment (Estimated as approximately 1 year) Physical function is assessed by EORTC-QLQ-C30 Physical Functioning scale or IL19. The physical function score is calculated by generating the raw score: (Q1+Q2+Q3+Q4+Q5)/5; and then generating the transformed score: (1-((raw score-1)/3)) x 100. The score ranges from 0 to 100. Higher scores indicate better physical function.
Part A and Part B: Time to Deterioration in Physical Function, as Measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (EORTC QLQ-C30) Physical Functioning Subscale and IL19 Randomization through end of treatment (Estimated as approximately 1 year) The EORTC QLQ-C30 is a 30-question patient-reported instrument used to assess multidimensional health-related quality of life (HRQoL) in cancer patients. Physical functioning is measured by the EORTC-QLQ-30 Physical Function Scale (five items). Response options range from 1) "Not at all" to 4) "Very much." The sum score is linearly transformed to the range 0 - 100. Higher scores represent better physical function.
Part A and Part B: Proportion of Time with High Side-Effect Burden, as Measured by Functional Assessment of Cancer Therapy - General Item 5 (FACT-GP5) Randomization through end of treatment (Estimated as approximately 1 year) FACT-GP5 is a single-item, patient-reported instrument for assessing overall treatment side-effect burden. Response options range from 0) "Not at all" to 4) "Very much." Higher scores represent higher symptom burden.
Part A and Part B: Change from Baseline in Overall Health-related Quality of Life, as Measured by the EORTC QLQ-C30 Global Health Status/Quality of Life Subscale Randomization through end of treatment (Estimated as approximately 1 year) The EORTC QLQ-C30 is a 30-question patient-reported instrument used to assess multidimensional HRQoL in cancer patients. Overall HRQoL is measured by the EORTC QLQ-30 Global Health Status/Quality of Life Subscale (two items). Response options range from 1) "very poor" to 7) "excellent." Scores are linearly transformed to the range 0 - 100. Higher scores represent better overall HRQoL.
Trial Locations
- Locations (364)
Cedars-Sinai Medical Center
🇺🇸Los Angeles, California, United States
Highlands Oncology Group
🇺🇸Springdale, Arkansas, United States
Ordensklinikum Linz GmbH Elisabethinen
🇦🇹Linz, Oberösterreich, Austria
Sirio-Libanes Brasilia - Centro de Oncologia - Asa Sul
🇧🇷Brasilia, Distrito Federal, Brazil
Liga Norte Riograndense Contra o Câncer
🇧🇷Natal, Rio Grande Do Norte, Brazil
ZNA Middelheim
🇧🇪Antwerp, Antwerpen, Belgium
Hospital Universitário Evangélico Mackenzie
🇧🇷Curitiba, Parana, Brazil
Icon Cancer Centre Wesley
🇦🇺Auchenflower, Queensland, Australia
Hospital Sírio Libanês
🇧🇷São Paulo, Brazil
Centro de Pesquisa Clínica do Instituto do Câncer do Ceará
🇧🇷Fortaleza, Ceará, Brazil
Icesp - Instituto Do Câncer Do Estado de São Paulo
🇧🇷São Paulo, Brazil
Centro Paulista de Oncologia Clínica
🇧🇷São Paulo, Brazil
Núcleo de Pesquisa Clínica da Rede São Camilo
🇧🇷São Paulo, Brazil
Hospital BP
🇧🇷Sao Paulo, São Paulo, Brazil
Centro de Tratamento de Tumores Botafogo para Oncoclinicas Rio de Janeiro SA
🇧🇷Rio de Janeiro, Brazil
CIUSSS- saguenay-Lac-Saint-Jean
🇨🇦Chicoutimi, Quebec, Canada
Instituto de Assistência Médica ao Servidor Público Estadual - IAMSPE/HSPE-FMO Conhecer Centro de Oncolog -T
🇧🇷São Paulo, Brazil
Instituto Nacional de Câncer - INCA
🇧🇷Rio de Janeiro, Brazil
Nemocnice AGEL Ostrava - Vitkovice a.s.
🇨🇿Ostrava, Ostrava Mě, Czechia
Faculdade de Medicina do ABC
🇧🇷Santo André, São Paulo, Brazil
Hôpital Foch
🇫🇷Suresnes, Hauts-de-Seine, France
Unité de Recherche Clinique du CISSS des Laurentides
🇨🇦Saint-Jérôme, Quebec, Canada
Fujian Cancer Hospital
🇨🇳Fuzhou, Fujian, China
The First Affiliated Hospital, Sun Yat-sen University
🇨🇳Guangzhou, Guangdong, China
Affiliated Hospital of Guangdong Medical University
🇨🇳Zhanjiang, Guangdong, China
Hôpital Robert Schuman
🇫🇷Vantoux, Lorraine, France
The First Affiliated Hospital of Xinxiang Medical University
🇨🇳Xinxiang, Henan, China
Asklepios Fachkliniken München-Gauting
🇩🇪Gauting, Bayern, Germany
Charité Campus Virchow-Klinikum
🇩🇪Berlin, Germany
Krankenhaus Martha-Maria Halle-Dölau
🇩🇪Halle, Sachsen-Anhalt, Germany
Onkologiezentrum Donauwörth
🇩🇪Donauwörth, Bayern, Germany
Centre Leon Berard
🇫🇷Lyon, Rhône-Alpes, France
Errikos Dunant Hospital Center
🇬🇷Athens, Attikí, Greece
CHU Bordeaux Haut-Leveque
🇫🇷Pessac, Aquitaine, France
Sainte Catherine Institut du Cancer Avignon Provence
🇫🇷Avignon, Vaucluse, France
Universitätsklinikum Münster - Albert Schweitzer Campus
🇩🇪Münster, Nordrhein-Westfalen, Germany
Centre Antoine-Lacassagne
🇫🇷Nice, Alpes-Maritimes, France
Fakultni nemocnice Bulovka
🇨🇿Prague, Praha 8, Czechia
University Hospital of Patras
🇬🇷Patras, Achaḯa, Greece
Centre de Cancérologie du Grand Montpellier
🇫🇷Montpellier, Languedoc-Roussillon, France
Thoraxklinik-Heidelberg gGmbH
🇩🇪Heidelberg, Baden-Württemberg, Germany
Mahatma Gandhi Cancer Hospital and Research Institute
🇮🇳Visakhapatnam, Andhra Pradesh, India
KLES Dr. Prabhakar Kore Hospital & M.R.C
🇮🇳Belagave, Karnataka, India
Klinikum Nürnberg Nord
🇩🇪Nürnberg, Bayern, Germany
Istituto Nazionale Tumori Regina Elena
🇮🇹Rome, Roma, Italy
Aichi Cancer Center Hospital
🇯🇵Nagoya, Aichi, Japan
Krishna Institute of Medical Sciences - Karad
🇮🇳Karad, Maharashtra, India
Országos Korányi Pulmonológiai Intézet
🇭🇺Budapest, Pest, Hungary
Miyagi Cancer Center
🇯🇵Natori, Miyagi, Japan
Saitama Medical University International Medical Center
🇯🇵Hidaka, Saitama, Japan
Istituto Nazionale Tumori IRCCS Fondazione Pascale
🇮🇹Napoli, Campania, Italy
Uzsoki Utcai Kórház
🇭🇺Budapest, Hungary
All India Institute of Medical Sciences
🇮🇳Bhubaneswar, Odisha, India
Fondazione Policlinico Universitario Agostino Gemelli
🇮🇹Roma, Lazio, Italy
Országos Onkológiai Intézet
🇭🇺Budapest, Hungary
Instituto Tumori Giovanni Paolo II
🇮🇹Bari, Puglia, Italy
National Cancer Center Hospital East
🇯🇵Kashiwa, Chiba, Japan
Chonnam National University Hwasun Hospital
🇰🇷Hwasun, Jeonranamdo, Korea, Republic of
Tokyo Metropolitan Komagome Hospital
🇯🇵Bunkyō-Ku, Tokyo, Japan
Gangnam Severance Hospital
🇰🇷Gangnam-gu, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Korea University Guro Hospital
🇰🇷Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Juntendo University Hospital
🇯🇵Bunkyo-ku, Tokyo, Japan
Tottori University Hospital
🇯🇵Yonago, Tottori, Japan
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Kyungpook National University Chilgok Hospital
🇰🇷Daegu, Taegu-Kwangyǒkshi, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
ETZ Elisabeth
🇳🇱Tilburg, Noord-Brabant, Netherlands
CHUAC-Hospital Teresa Herrera
🇪🇸A Coruña, A Coruña [, Spain
Hospital Universitari Dexeusa
🇪🇸Barcelona, Catalunya [Cataluña], Spain
Asan Medical Center
🇰🇷Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Higiea Oncologia
🇲🇽Mexico City, Distrito Federal, Mexico
Medische Centrum Leeuwarden
🇳🇱Leeuwarden, Fryslân, Netherlands
The Catholic University of Korea, Yeouido St. Mary's Hospital
🇰🇷Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Arké SMO S.A de C.V
🇲🇽Veracruz, Mexico
Jeroen Bosch ziekenhuis
🇳🇱Den Bosch, Noord-Brabant, Netherlands
Hospital Universitari Son Espases
🇪🇸Palma De Mallorca, Balears [Baleares], Spain
CHUS - Hospital Clinico Universitario
🇪🇸Santiago de Compostela, A Coruña [La Coruña], Spain
Adana Medical Park Seyhan Hastanesi
🇹🇷Adana, Turkey
Dicle Üniversitesi
🇹🇷Diyarbakir, Turkey
Ondokuz Mayıs Universitesi
🇹🇷Samsun, Turkey
Hospital Jerez de la Frontera
🇪🇸Jerez De La Frontera, Cádiz, Spain
Ankara Etlik City Hospital
🇹🇷Ankara, Turkey
Akdeniz Universitesi Hastanesi
🇹🇷Antalya, Turkey
İ.A.Ü VM Medical Park Florya Hastanesi
🇹🇷Istanbul, Turkey
Hospital Infanta Cristina
🇪🇸Badajoz, Spain
Hospital Insular de Gran Canaria
🇪🇸Las Palmas de Gran Canaria, Las Palmas, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Madrid, Comunidad De, Spain
Ege Universitesi Hastanesi
🇹🇷Izmir, Turkey
Hospital Universitario Quironsalud Madrid
🇪🇸Pozuelo de Alarcon, Madrid, Spain
Hospital Regional Universitario
🇪🇸Málaga, Spain
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi
🇹🇷Ankara, Turkey
Adana City Hospital
🇹🇷Adana, Turkey
Ankara Bilkent Şehir Hastanesi
🇹🇷Ankara, Turkey
zmir Katip Çelebi Üniversitesi Atatürk Eitim Ve Aratrma Hastanesi
🇹🇷Izmir, Turkey
National Taiwan University Cancer Center (NTUCC)
🇨🇳Taipei City, Taipei, Taiwan
Community Cancer Center North
🇺🇸Indianapolis, Indiana, United States
Miami Cancer Institute at Baptist Health, Inc.
🇺🇸Miami, Florida, United States
Indiana University Melvin and Bren Simon Cancer Center
🇺🇸Indianapolis, Indiana, United States
University of Texas MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
St. Antonius Ziekenhuis, locatie Utrecht
🇳🇱Utrecht, Netherlands
University General Hospital of Heraklion
🇬🇷Heraklion, Irakleío, Greece
European Interbalkan Medical Center
🇬🇷Thessaloniki, Thessaloníki, Greece
G. Papanikolaou General Hospital
🇬🇷Thessaloniki, Thessaloníki, Greece
AZ Glorieux Ronse
🇧🇪Ronse, Belgium
Allina Health Cancer Institute
🇺🇸Minneapolis, Minnesota, United States
Rajiv Gandhi Cancer Institute And Research Centre
🇮🇳New Delhi, Delhi, India
Hospital Brasilia
🇧🇷Lago sul, Distrito Federal, Brazil
Clinica Amo - Rio Vermelho
🇧🇷Salvador, Bahia, Brazil
Oncominas
🇧🇷Pouso Alegre, Minas Gerais, Brazil
Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godinne
🇧🇪Yvoir, Namur, Belgium
Ashwin Hospital
🇮🇳Coimbatore, Tamil Nadu, India
ONCOSITE - Centro de Pesquisa Clinica em Oncologia
🇧🇷Ijui, Rio Grande Do Sul, Brazil
Preparaciones Oncológicas S.C.
🇲🇽León, Guanajuato, Mexico
LungenClinic Grosshansdorf
🇩🇪Grosshansdorf, Schleswig-Holstein, Germany
Hospital São Lucas da PUCRS
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Boston Medical Center
🇺🇸Boston, Massachusetts, United States
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
Næstved Sygehus
🇩🇰Næstved, Sjælland, Denmark
Roskilde University Hospital
🇩🇰Roskilde, Sjælland, Denmark
Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
Wannan Medical College Yijishan Hospital
🇨🇳Wuhu, Anhui, China
Liuzhou People's Hospital
🇨🇳Liuzhou, Guangxi, China
The First Affiliated Hospital of Guangzhou Medical University
🇨🇳Guangzhou, Guangdong, China
Beijing Cancer hospital
🇨🇳Beijing, Beijing, China
The First Affiliated Hospital of the Third Military Medical University
🇨🇳Shapingba, Chongqing, China
Hainan General Hospital
🇨🇳Haikou, Hainan, China
Harbin Medical University Cancer Hospital
🇨🇳Harbin, Heilongjiang, China
Wuhan Union Hospital
🇨🇳Wuhan, Hubei, China
Xiangyang Central Hospital
🇨🇳Xiangyang, Hubei, China
Renmin Hospital of Wuhan University
🇨🇳Wuhan, Hubei, China
Hunan Cancer Hospital
🇨🇳Changsha, Hunan, China
ZhuZhou Central Hospital
🇨🇳Zhuzhou, Hunan, China
The First People's Hospital of Changzhou
🇨🇳Changzhou, Jiangsu, China
Nanjing First Hospital
🇨🇳Nanjing, Jiangsu, China
Jiangsu Province Hospital
🇨🇳Nanjing, Jiangsu, China
Nantong Tumor Hospital
🇨🇳Nantong, Jiangsu, China
The First Affiliated Hospital of Nanchang University
🇨🇳Nanchang, Jiangxi, China
Jilin Cancer Hospital
🇨🇳Changchun, Jilin, China
Jinan Central Hospital
🇨🇳Jinan, Shandong, China
Tangdu Hospital of Fourth Military Medical University of Chinese People's Liberation Army
🇨🇳Xi'an, Shaanxi, China
The First Affiliated Hospital of Xi'an Jiaotong University
🇨🇳Xi'an, Shaanxi, China
Shandong Cancer Hospital
🇨🇳Jinan, Shandong, China
LinYi Cancer Hospital
🇨🇳Linyi, Shandong, China
Shanghai Chest Hospital
🇨🇳Shanghai, Shanghai, China
The First Affiliated Hospital, Zhejiang University
🇨🇳Hangzhou, Zhejiang, China
Taizhou Hospital of Zhejiang Province
🇨🇳Linhai, Zhejiang, China
The Third People's Hospital of Chengdu (CDTPH)
🇨🇳Chengdu, Sichuan, China
Sichuan Cancer hospital
🇨🇳Chengdu, Sichuan, China
West China Hospital, Sichuan University
🇨🇳ChengDu, Sichuan, China
Tianjin Medical University Cancer Institute and Hospital
🇨🇳Tianjin, Tianjin, China
Xinjiang Medical University Cancer Hospital - Urumqi
🇨🇳Urumqi, Xinjiang, China
Sir Run Run Shaw Hospital
🇨🇳Hangzhou, Zhejiang, China
The First Affiliated Hospital of Xinjiang Medical University
🇨🇳Urumchi, Xinjiang, China
Hwa Mei Hospital University of Chinese Academy of Sciences
🇨🇳Ningbo, Zhejiang, China
Yichang Central People's Hospital
🇨🇳Yichang, China
Policlinico "G. Rodolico"
🇮🇹Catania, Sicilia, Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
🇮🇹Bologna, Italy
Istituto Oncologico Veneto IRCCS
🇮🇹Padova, Italy
Ospedale di Circolo e Fondazione Macchi Varese
🇮🇹Varese, Italy
St James's University Hospital
🇬🇧Leeds, United Kingdom
The Christie NHS Foundation Trust
🇬🇧Manchester, Withington, United Kingdom
Providence Portland Medical Center
🇺🇸Portland, Oregon, United States
Providence St. Vincent Medical Center
🇺🇸Portland, Oregon, United States
Bezmialem Vakf Üniversitesi
🇹🇷Istanbul, Turkey
Kanagawa Cardiovascular and Respiratory Center
🇯🇵Yokohama, Kanagawa, Japan
Hokkaido University Hospital
🇯🇵Sapporo, Hokkaido, Japan
Himeji Medical Center
🇯🇵Himeji, Hyogo, Japan
National Hospital Organization Kinki-chuo Chest Medical Center
🇯🇵Sakai, Osaka, Japan
Kindai University Hospital- Osakasayama Campus
🇯🇵Osakasayama, Osaka, Japan
Kanazawa University Hospital
🇯🇵Kanazawa, Ishikawa, Japan
Kansai Medical University Hospital
🇯🇵Hirakata, Osaka, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata-shi, Niigata, Japan
National Hospital Organization Kyushu Cancer Center
🇯🇵Fukuoka, Japan
National Hospital Organization Yamaguchi Ube Medical Center
🇯🇵Ube, Yamaguchi, Japan
University Hospital,Kyoto Prefectural University of Medicine
🇯🇵Kyoto, Japan
Wakayama Medical University Hospital
🇯🇵Wakayama, Japan
Okayama University Hospital
🇯🇵Okayama, Japan
Kyushu University Hospital
🇯🇵Fukuoka, Japan
National Cancer Center
🇰🇷Goyang-si, Kyǒnggi-do, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Seoul-teukbyeolsi, Korea, Republic of
Keimyung University Dongsan Hospital
🇰🇷Daegu, Taegu-Kwangyǒkshi, Korea, Republic of
Instituto Catalan de Oncologia - Hospital Duran i Reynals
🇪🇸Hospitalet de Llobregat, Barcelona [Barcelona], Spain
Parc de Salut Mar - Hospital del Mar
🇪🇸Barcelona, Barcelona [Barcelona], Spain
Hospital Universitario Ramón y Cajal
🇪🇸Madrid, Madrid, Comunidad De, Spain
Complejo Asistencial Universitario de León - Hospital de León
🇪🇸León, Castilla Y León, Spain
Hospital Universitario Virgen Del Rocio
🇪🇸Sevilla, Spain
Evangelische Lungenklinik Berlin
🇩🇪Berlin, Germany
Hämato-Onkologie Hamburg, Prof. Laack und Partner
🇩🇪Hamburg, Germany
SRH Wald-Klinikum Gera
🇩🇪Gera, Thüringen, Germany
Hospices Civils de Lyon - Hopital Louis Pradel
🇫🇷Bron, Rhône, France
Kanagawa cancer center
🇯🇵Yokohama, Kanagawa, Japan
Tampa General Hospital
🇺🇸Tampa, Florida, United States
Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala
🇺🇸Ocala, Florida, United States
Millennium Oncology - Hollywood
🇺🇸Hollywood, Florida, United States
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
🇺🇸Torrance, California, United States
Comprehensive Hematology Oncology
🇺🇸Saint Petersburg, Florida, United States
University Cancer & Blood Center, LLC
🇺🇸Athens, Georgia, United States
Springfield Clinic Main Campus
🇺🇸Springfield, Illinois, United States
University of Kentucky Chandler Medical Center
🇺🇸Lexington, Kentucky, United States
Cancer and Hematology Centers of Western Michigan
🇺🇸Grand Rapids, Michigan, United States
HealthPartners Cancer Research Center
🇺🇸Saint Paul, Minnesota, United States
Lahey Hospital & Medical Center
🇺🇸Burlington, Massachusetts, United States
Summit Health
🇺🇸Florham Park, New Jersey, United States
The Valley Hospital
🇺🇸Paramus, New Jersey, United States
Perlmutter Cancer Center at NYU Langone Hospital - Long Island
🇺🇸Mineola, New York, United States
Capital Health Medical Center - Hopewell
🇺🇸Pennington, New Jersey, United States
University of New Mexico Comprehensive Cancer Center
🇺🇸Albuquerque, New Mexico, United States
Northwell Health/ RJ Zuckerberg Cancer Center
🇺🇸Lake Success, New York, United States
Clinical Research Alliance
🇺🇸Westbury, New York, United States
Asante Rogue Regional Medical Center
🇺🇸Medford, Oregon, United States
Laura and Isaac Perlmutter Cancer Center
🇺🇸New York, New York, United States
Baptist Memorial Hospital-Memphis
🇺🇸Memphis, Tennessee, United States
Baylor Scott & White Medical Center - Temple
🇺🇸Temple, Texas, United States
Sunshine Coast University Hospital
🇦🇺Birtinya, Queensland, Australia
Gosford Hospital
🇦🇺Gosford, New South Wales, Australia
Gold Coast University Hospital
🇦🇺Southport, Queensland, Australia
Mackay Base Hospital
🇦🇺Mackay, Queensland, Australia
The Townsville Hospital
🇦🇺Townsville, Queensland, Australia
Royal Adelaide Hospital
🇦🇺Adelaide, South Australia, Australia
Ballarat Health Services
🇦🇺Ballarat Central, Victoria, Australia
Goulburn Valley Health
🇦🇺Shepparton, Victoria, Australia
St Vincent's Hospital
🇦🇺Melbourne, Victoria, Australia
Sir Charles Gairdner Hospital
🇦🇺Perth, Western Australia, Australia
Klinik Floridsdorf
🇦🇹Wien, Austria
AZ Sint-Maarten, Campus Leopoldstraat 2
🇧🇪Mechelen, Antwerpen, Belgium
CHU de Toulouse - Hopital Larrey
🇫🇷Toulouse, Haute-Garonne, France
Nouvel Hôpital Civil (NHC)
🇫🇷Strasbourg, Alsace, France
Centre Hospitalier intercommunal de Toulon La Seyne sur Mer
🇫🇷Toulon, Provence-Alpes-Côte-d'Azur, France
Institut Curie
🇫🇷Paris, France
Agios Savvas Regional Cancer Hospital
🇬🇷Athens, Attikí, Greece
Sotiria Thoracic Diseases Hospital of Athens
🇬🇷Athens, Attikí, Greece
Farkasgyepui Tudogyogyintezet
🇭🇺Farkasgyepű, Veszprém, Hungary
Nizam's Institute of Medical Sciences
🇮🇳Hyderabad, Telangana, India
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento
🇮🇹Verona, Veneto, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
🇮🇹Milan, Lombardia, Italy
National Hospital Organization Shikoku Cancer Center
🇯🇵Matsuyama, Ehime, Japan
Tominaga Hospital
🇯🇵Nagaizumi-cho,Sunto-gun, Shizuoka, Japan
Chungbuk National University Hospital
🇰🇷Cheongju-si, Chungcheongbuk-do [Chungbuk], Korea, Republic of
The Catholic University Of Korea St. Vincent's Hospital
🇰🇷Suwon-si, Kyǒnggi-do, Korea, Republic of
Pusan National University Yangsan Hospital
🇰🇷Yangsan, Kyǒngsangnam-do, Korea, Republic of
Health Pharma Professional Research S.A. de C.V:
🇲🇽Ciudad de México, Distrito Federal, Mexico
Hanyang University Seoul Hospital
🇰🇷Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Hospital Universitario Dr. Jose Eleuterio Gonzalez
🇲🇽Monterrey, Nuevo León, Mexico
Drammen Sykehus, Vestre Viken HF
🇳🇴Drammen, Buskerud, Norway
Leids Universitair Medisch Centrum
🇳🇱Leiden, Zuid-Holland, Netherlands
Akershus Universitetssykehus
🇳🇴Lørenskog, Akershus, Norway
Erasmus Medisch Centrum
🇳🇱Rotterdam, Zuid-Holland, Netherlands
Haukeland Universitetssjukehus
🇳🇴Bergen, Hordaland, Norway
MICS Centrum Medyczne Torun
🇵🇱Torun, Kujawsko-pomorskie, Poland
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Barcelona [Barcelona], Spain
Hospital Clinico de Valencia
🇪🇸Valencia, Valenciana, Comunitat, Spain
Västmanlands Sjukhus Västerås
🇸🇪Västerås, Västmanlands Län [se-19], Sweden
Mälarsjukhuset
🇸🇪Eskilstuna, Södermanlands Län [se-04], Sweden
National Taiwan University Hospital Yun-Lin Branch Dou-Liou Region
🇨🇳Douliu, Yunlin, Taiwan
Uludag Universitesi
🇹🇷Bursa, Turkey
Memorial Antalya Hospital
🇹🇷Antalya, Turkey
Aberdeen Royal Infirmary
🇬🇧Aberdeen, Aberdeen City, United Kingdom
Mount Vernon Hospital
🇬🇧Northwood, Hillingdon, United Kingdom
Ninewells Hospital and Medical School
🇬🇧Dundee, Dundee City, United Kingdom
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
🇹🇷Istanbul, Turkey
Kocaeli Üniversitesi
🇹🇷Kocaeli, Turkey
Weston Park Hospital
🇬🇧Sheffield, England, United Kingdom
New Cross Hospital
🇬🇧Wolverhampton, United Kingdom
Avix Investigación Clinica, S.C.
🇲🇽Monterrey, Nuevo León, Mexico
Sahyadri Super Speciality Hospital
🇮🇳Pune, Maharashtra, India
Medisch Spectrum Twente
🇳🇱Enschede, Overijssel, Netherlands
Yale University School of Medicine
🇺🇸New Haven, Connecticut, United States
Hospital São Domingos
🇧🇷Bequimao, Maranhão, Brazil
Regional Cancer Centre - Thiruvananthapuram
🇮🇳Thiruvananthapuram, Kerala, India
COE Ensino e Pesquisa
🇧🇷São José dos Campos, São Paulo, Brazil
Instituto D'Or de Pesquisa e Ensino (IDOR)
🇧🇷Sao Paulo, São Paulo, Brazil
Kolhapur Cancer Centre Private Limited
🇮🇳Kolhāpur, Maharashtra, India
CHU Lille - Institut Coeur Poumon
🇫🇷Lille Cedex, Nord, France
Hospital de Cancer de Londrina
🇧🇷Londrina, Paraná, Brazil
Landeskrankenhaus Feldkirch
🇦🇹Feldkirch, Vorarlberg, Austria
Institut Jean Godinot
🇫🇷Reims, Marne, France
Gustave Roussy
🇫🇷Villejuif, Val-de-Marne, France
Centre Hospitalier Universitaire de Poitiers
🇫🇷Poitiers, Vienne, France
Jawaharlal Institute Of Postgraduate Medical Education And Research
🇮🇳Puducherry, India
Oncare - Unidad Valle
🇲🇽San Pedro Garza García, Nuevo León, Mexico
Clinica Integral Internacional de Oncología
🇲🇽Puebla, Mexico
Centrul medical Focus
🇷🇴București, Romania
UniversitätsSpital Zürich
🇨🇭Zürich, Switzerland
Changhua Christian Hospital
🇨🇳Changhua, Taiwan
Cheltenham General Hospital
🇬🇧Cheltenham, Gloucestershire, United Kingdom
CHUV (centre hospitalier universitaire vaudois)
🇨🇭Lausanne, Vaud, Switzerland
Universitaetsklinikum Tuebingen
🇩🇪Tübingen, Baden-Württemberg, Germany
Hospital Paulistano
🇧🇷Sao Paulo, São Paulo, Brazil
Health Pharma Querétaro
🇲🇽Juriquilla, Querétaro, Mexico
Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou
🇫🇷Rennes, Ille-et-Vilaine, France
Institut de Cancérologie de l'Ouest
🇫🇷Saint Herblain, Loire-Atlantique, France
Japanese Foundation for Cancer Research
🇯🇵Koto, Tokyo, Japan
Sykehuset Innlandet HF Gjøvik
🇳🇴Gjøvik, Oppland, Norway
Oslo Universitetssykehus Ullevål
🇳🇴Oslo, Norway
One Day Med
🇵🇱Szczecin, Zachodniopomorskie, Poland
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej
🇵🇱Kielce, Świętokrzyskie, Poland
S C Oncocenter Oncologie Clinica S R L
🇷🇴Timișoara, Timiș, Romania
Cabinet Medical Oncomed
🇷🇴Timișoara, Timiș, Romania
Chang Gung Memorial Hospital at Kaohsiung
🇨🇳Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
Chang Gung Medical Foundation-Linkou Branch
🇨🇳Taoyuan, Taiwan
Bacs-Kiskun Varmegyei Oktatokorhaz
🇭🇺Kecskemét, Bács-Kiskun, Hungary
Actualidad Basada en la Investigación del Cáncer
🇲🇽Guadalajara, Jalisco, Mexico
Centro Hospitalar do Porto - Hospital de Santo António
🇵🇹Porto, Portugal
Centrul de Oncologie "Sfântul Nectarie"
🇷🇴Craiova, Dolj, Romania
Chi Mei Hospital - Liouying Branch
🇨🇳Tainan City, Tainan, Taiwan
Grant Medical Foundation - Ruby Hall Clinic
🇮🇳Pune, Maharashtra, India
Renati Innovation
🇲🇽Guadalajara, Jalisco, Mexico
Universitaetsklinikum Freiburg
🇩🇪Freiburg, Baden-Württemberg, Germany
HCG Manavata Cancer Centre
🇮🇳Nashik, Maharashtra, India
Tata Memorial Centre - Homi Bhabha Cancer Hospital
🇮🇳Varanasi, Uttar Pradesh, India
Champalimaud Foundation
🇵🇹Lisbon, Lisboa, Portugal
Centro Hospitalar E Universitário De Coimbra
🇵🇹Coimbra, Portugal
Hospital CUF Porto
🇵🇹Porto, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil, EPE
🇵🇹Porto, Portugal
Institutul Oncologic
🇷🇴Cluj-Napoca, Cluj, Romania
Ovidius Clinical Hospital OCH
🇷🇴Ovidiu, Constanța, Romania
Gral Medical Diagnostic Center
🇷🇴București, Romania
Buddhist Dalin Tzu Chi General Hospital
🇨🇳Chiayi, Taiwan
Kaohsiung Medical University Hospital
🇨🇳Kaohsiung, Taiwan
SRV Hospitals
🇮🇳Bengaluru, Karnataka, India
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Postgraduate Institute of Medical Education & Research
🇮🇳Chandigarh, India
Centro Onco-Hematológico Roma (COHR)
🇲🇽Mexico City, Distrito Federal, Mexico
Centro de Investigacion Clinica de Oaxaca
🇲🇽Oaxaca, Mexico
St. Olavs Hospital
🇳🇴Trondheim, Sør-Trøndelag, Norway
Hospital Pulido Valente
🇵🇹Lisbon, Lisboa, Portugal
Hospital da Luz Lisboa
🇵🇹Lisboa, Portugal
Lotus-Med
🇷🇴Bucharest, Bucuresti, Romania
Banaras Hindu University
🇮🇳Varanasi, Uttar Pradesh, India
Tata Memorial Hospital
🇮🇳Mumbai, Maharashtra, India
Kantonsspital Winterthur
🇨🇭Winterthur, Switzerland
Clinique Saint Pierre
🇧🇪Ottignies, Brabant Wallon, Belgium
UZ Gent
🇧🇪Gent, Oost-Vlaanderen, Belgium
AZ Sint-Jan Brugge-Oostende AV
🇧🇪Brugge, West-Vlaanderen, Belgium
AZ Groeninge Campus Kennedylaan
🇧🇪Kortrijk, West-Vlaanderen, Belgium
Clearview Cancer Institute
🇺🇸Huntsville, Alabama, United States
CIO - Centro de Inmuno-Oncología de Occidente
🇲🇽Guadalajara, Jalisco, Mexico
PanAmerican Clinical Research - Guadalajara
🇲🇽Guadalajara, Jalisco, Mexico
Complejo Hospitalario de Navarra
🇪🇸Pamplona, Navarra, Spain
Stavanger Universitetssykehus
🇳🇴Stavanger, Rogaland, Norway
Chung Shan Medical University Hospital
🇨🇳Taichung City, Taichung, Taiwan
Helios Klinikum Emil von Behring Berlin-Zehlendorf
🇩🇪Berlin, Germany
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Hospital Tacchini
🇧🇷Bento Gonçalves, Rio Grande Do Sul, Brazil
Hualien Tzu Chi Medical Center
🇨🇳Hualien City, Hualien, Taiwan
Tongji Hospital Tongji Medical,Science & Technology
🇨🇳Wuhan, Hubei, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, Zhejiang, China
Banner MD Anderson Cancer Center
🇺🇸Gilbert, Arizona, United States
Millennium Oncology Research Clinic
🇺🇸Hollywood, Florida, United States
Allina Health Cancer Institute - Abbott Northwestern Hospital
🇺🇸Minneapolis, Minnesota, United States
Comprehensive Cancer Centers of Nevada
🇺🇸Las Vegas, Nevada, United States
The Valley Hospital, Inc.
🇺🇸Paramus, New Jersey, United States
Lifespan Cancer Institute
🇺🇸Providence, Rhode Island, United States
Lexington Medical Center
🇺🇸West Columbia, South Carolina, United States
CHIREC - site delta
🇧🇪Auderghem, Bruxelles-Capitale, Région De, Belgium
Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA
🇧🇷Rio de Janeiro, Brazil
Cancer Hospital Chinese Academy of Medical Science
🇨🇳Beijing, Beijing, China
Manhattan Eye, Ear and Throat Hospital
🇺🇸New York, New York, United States
UZ Leuven
🇧🇪Leuven, Vlaams-Brabant, Belgium
Parkview Research Center at Parkview Regional Medical Center
🇺🇸Fort Wayne, Indiana, United States
CHI Saint Joseph Cancer Center - East
🇺🇸Lexington, Kentucky, United States
Tennessee Oncology
🇺🇸Nashville, Tennessee, United States
USO - US Oncology Research Network
🇺🇸Nashville, Tennessee, United States
Related News
Olomorasib Combo Elicits Favorable Efficacy in NSCLC - Targeted Oncology
- Prev
- 1
- Next